John A. Taylor, III, MD, MS, discussed the new wealth of options in non–muscle invasive bladder cancer, specifically highlighting detalimogene voraplasmid. In a recent interview with Urology Times®, ...

"A lot of times…decreased desire is affected by everything else: pain with sex, orgasm, arousal. Because if none of that is good, then desire isn't going to be good either," says Anna Myers, CNP. In a ...

Experts briefly discuss 3 new FDA-approved treatments for patients who are unresponsive to bacille Calmette-Guérin (BCG) in the last 5 years—pembrolizumab, nogapendekin alfa inbakicept-pmln, and ...

Panelists discuss how future trials in metastatic castration-resistant prostate cancer (mCRPC) should focus on developing reliable biomarker-driven treatment selection strategies to optimize ...

“What's really cool about overactive bladder is that, it's not like high blood pressure. They do not have to leave this office with a pill in hand," says Anna Myers, CNP. When evaluating a patient for ...

Where are you using these treatments in your practice, and how do you choose between them for BCG-unresponsive patients? How have these advances changed the timing of radical cystectomy for patients?

Panelists discuss how the phase 3 DORA trial investigates the combination of standard of care darolutamide with radium-223 in patients with metastatic castration-resistant prostate cancer (mCRPC), ...

An expert discusses how TAR-200 shows promise for non–muscle invasive bladder cancer (NMIBC) treatment, with medical professionals optimistic about its targeted delivery, potentially improved outcomes ...

“One important aspect to get across…is that access to this EAP is pretty easy," says Suzanne B. Merrill, MD, FACS. An expanded access program (EAP) to provide recombinant BCG (rBCG) in the US was ...

“The impact on bone health is really significant with long-term androgen suppression," says Dr Louise Kostos. In a recent study of combination therapies for the treatment of locally advanced and ...

"There is evidence for a direct link between the exposures you get by doing your job as a firefighter and then developing cancer down the road," says Sima P. Porten, MD, MPH. Firefighters face an ...

NeuroSAFE RARP improves erectile function at 12 months compared to standard RARP, with higher nerve-sparing rates. Initial urinary continence benefits at 3 months with NeuroSAFE are not sustained at 6 ...